苯溴马隆联合小剂量秋水仙碱治疗痛风患者的效果及安全性分析

Abstract
Figure/Table
References (24)
Related Citation (15)

Download: PDF (554 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect and safety analysis of Benzbromarone combined with low dose of Colchicine in the treatment of gout. Methods A total of 90 gout patients in Huizhou Third People′s Hospital of Guangdong Province from March 2016 to March 2019 were divided into control group (45 cases) and research group (45 cases) by random number table method. The control group was given routine treatment combined with Benzbromarone, while the research group was given low dose of Colchicine maintenance treatment on the basis of the control group. The clinical efficiency of the two groups was observed, and the visual analogue scale (VAS) scores of the two groups were compared before and after treatment. The levels of uric acid, erythrocyte sedimentation rate, creatinine, serum nitric oxide (NO), endothelin-1 (ET-1), amyloid protein (SAA) and high sensitive C-reactive protein (hs-CRP) were measured before and after treatment. The number of acute episodes and adverse reactions of gastrointestinal tract in the two groups were counted. Results The total effective rate of the research group was higher than that of the control group (P ＜ 0.05). After treatment, the VAS scores of the two groups were decreased, and the research group was lower than that of the control group (P ＜ 0.05). The number of pain episodes in the research group was significantly lower than that in the control group (P ＜ 0.05). After treatment, the levels of uric acid, erythrocyte sedimentation rate and serum ET-1, SAA, hs-CRP were decreased, and the level of serum NO was increased. The level of uric acid, erythrocyte sedimentation rate and serum ET-1, SAA, hs-CRP in the research group were lower than those in the control group, and the level of serum NO was higher than that in the control group (P ＜ 0.05). The incidence of gastrointestinal adverse reactions in the research group was significantly lower than that in the control group (P ＜ 0.05). Conclusion Benzbromarone combined with low dose of Colchicine can improve the clinical efficacy of gout patients, improve pain symptoms and vascular endothelial function, inhibit inflammatory response, decrease the number of acute episodes, and reduce the level of serum uric acid, and alleviate gastrointestinal adverse reactions.

Key words： Colchicine Gout Benzbromarone Adverse reactions

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Guan LUO Weijun

Cite this article:

LI Guan LUO Weijun. Effect and safety analysis of Benzbromarone combined with low dose of Colchicine in the treatment of gout[J]. 中国医药导报, 2020, 17(4): 14-17.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I4/14

[1] 周春言，李琴.自拟痛风方联合塞来昔布治疗湿热夹瘀型痛风性关节炎临床研究[J].国际中医中药杂志，2018， 40（9）：818-821.
[2] Perez-Ruiz F，Dalbeth N. Combination urate-lowering therapy in the treatment of gout： What is the evidence? [J] Semin Arthritis Rheum，2019，48（4）：658-668.
[3] Terkeltaub R，Saag KG，Goldfarb DS，et al. Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout [J]. Rheumatology（Oxford），2018，58（1）：61-69.
[4] 蔡炜.不同剂量秋水仙碱治疗痛风性关节炎的效果比较[J].中国现代医生，2018，56（35）：121-123.
[5] 中华医学会内分泌学分会.高尿酸血症和痛风治疗的中国专家共识[J].中华内分泌代谢杂志，2013，29（11）：913-920.
[6] Richette P，Doherty M，Pascual E，et al. 2016 updated EULAR evidence-based recommendations for the management of gout [J]. Ann Rheum Dis，2017，76（1）：29-42.
[7] 常兴和，门九章，李霞，等.金匮肾气丸治疗痛风的疗效观察[J].世界中西医结合杂志，2014，9（2）：175-176.
[8] Martin KD，Van Buren JP，Wake J，et al. Comparison of visual analog pain score reported to physician vs nurse [J]. Foot Ankle Int，2018，39（3）：300-303.
[9] Joo K，Kwon SR，Lim M J，et al. Prevention of Comorbidity and Acute Attack of Gout by Uric Acid Lowering Therapy [J]. J Korean Med Sci，2014，29（5）：657-661.
[10] Towiwat P，Chhana A，Dalbeth N. The anatomical pathology of gout： a systematic literature review[J].BMC Musculoskelet Disor，2019，20（1）：140.
[11] Smith E，Hoy D，Cross M，et al. The global burden of gout：estimates from the Global Burden of Disease 2010 study [J]. Ann Rheum Dis，2014，73（8）：1470-1476.
[12] 古洁若，招淑珠.高尿酸血症及痛风达标治疗的必由之路——健康管理[J].新医学，2017，48（6）：365-368.
[13] 彭春梅，青玉风，何泳龙，等.依托考昔治疗痛风致发疹性药疹1例并文献复习[J].成都医学院学报，2018，13（5）：648-650.
[14] 邱芳晖，张洪柱.刺血疗法治疗急性痛风性关节炎的效果及对血清代谢产物的影响[J].中国医药导报，2018， 15（12）：135-139，封3.
[15] 赵力，邹和建，薛愉. 痛风与心血管疾病[J].中国实用内科杂志，2018，38（12）：21-25.
[16] Dalbeth N，Lauterio TJ，Wolfe HR. Mechanism of action of colchicine in the treatment of gout [J]. Clin Ther，2014， 36（10）：1465-1479.
[17] 苏金梅，曾小峰. 重视痛风疾病的诊治[J].中国实用内科杂志，2018，38（12）：7-8.
[18] 朱丹，青玉凤，李青，等.我国川东北地区男性原发性痛风患者中不同原因高尿酸血症者危险因素及临床特点分析[J].成都医学院学报，2018，13（1）：45-49.
[19] 陶晓璇，李刚，张增珠，等.秋水仙碱致不良反应的文献分析[J].中国药业，2016，25（2）：84-86.
[20] 杨彦龙，李小琴，史静，等.小剂量秋水仙碱联合得宝松治疗急性痛风性关节炎的疗效分析[J].检验医学与临床，2016，13（15）：2103-2105.
[21] 陆世凯.不同剂量秋水仙碱治疗痛风性关节炎患者的临床效果比较[J].中华全科医学，2017，15（10）：1700-1703.
[22] 张帆，赵春辉，陈丽，等.秋水仙碱对高脂喂养大鼠动脉血管炎症反应的影响研究[J].中国医药科学，2018，8（07）：45-47.
[23] Liu J，Zhong F，Han S，et al. A Clinical Study of Combined Therapy of Colchicine and Benzbromarone Capsules in the Treatment of Gouty Arthritis at Non-Acute Episode Stage[J]. J Kunming Med Univ，2018，39（2）：71-75.
[24] 蒙龙，李娟，龙锐，等.小剂量与常规剂量秋水仙碱治疗急性痛风性关节炎的系统评价[J].中国临床药理学与治疗学，2014，19（6）：656-662.